Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-50,000
Closed -$6.71M 3805
2021
Q4
$6.71M Buy
50,000
+5,200
+12% +$747K ﹤0.01% 1792
2021
Q3
$6.13M Hold
44,800
﹤0.01% 1902
2021
Q2
$4.78M Sell
44,800
-56,400
-56% -$5.42M ﹤0.01% 2113
2021
Q1
$9.09M Buy
101,200
+4,800
+5% +$451K ﹤0.01% 1641
2020
Q4
$8.91M Buy
96,400
+85,200
+761% +$7.61M ﹤0.01% 1656
2020
Q3
$1.15M Buy
+11,200
New +$1.17M ﹤0.01% 2829

Other funds holding DXCM

Credit Suisse's DXCM Position: Q1 2024 in Review

Credit Suisse reduced its DexCom (DXCM) stake by 2.2% in Q1 2024, selling an estimated $5.29M and leaving 1,916,217 shares worth $266M. The position accounts for 0.25% of the portfolio, ranked #67.

Credit Suisse first reported a position in DXCM in Q2 2013 and has held it in 44 quarters since. The position peaked at $549M in Q3 2021. 1,032 funds tracked by Wall St. Rank hold DXCM as of Q1 2024.

  • Credit Suisse held 1,916,217 shares of DexCom worth $266M as of Q1 2024.
  • Credit Suisse sold 42,104 DexCom shares in Q1 2024, an estimated $5.29M.
  • DexCom made up 0.25% of Credit Suisse's portfolio in Q1 2024, its #67 holding.
  • Credit Suisse first reported a position in DexCom in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's DexCom position peaked at $549M in Q3 2021.
  • 1,032 funds tracked by Wall St. Rank held DexCom as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.